Literature DB >> 24424167

Diagnosis and classification of idiopathic pulmonary fibrosis.

Alana Kekevian1, M Eric Gershwin2, Christopher Chang3.   

Abstract

Idiopathic pulmonary fibrosis is a difficult disease to diagnose. Idiopathic pulmonary fibrosis is a member of a class of diseases known as idiopathic interstitial pneumonias. Other members include nonspecific interstitial pneumonia, cryptogenic organizing pneumonia, acute interstitial pneumonia, respiratory bronchiolitis-associated interstitial lung disease, desquamative interstitial pneumonia, and lymphocytic interstitial pneumonia. Usual interstitial pneumonia (UIP) is the pathological equivalent of idiopathic pulmonary fibrosis. Prior to 2011, the diagnosis was based on major and minor criteria, but because these criteria were not evidence based, the criteria were modified by consensus from the American Thoracic Society, the European Respiratory Society, the Japanese Respiratory Society, and the Latin American Thoracic Association. These new criteria now include satisfying three core requirements, including exclusion of other possible cause of interstitial lung disease, specific findings of usual interstitial pneumonia on high resolution computed tomography, and a combination of "possible UIP" findings on high resolution computed tomography and UIP findings on lung biopsy. Idiopathic pulmonary fibrosis is a severe, progressive disease with limited treatment options, and exacerbations are associated with a high degree of morbidity and mortality.
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Acute interstitial pneumonia (AIP); Cryptogenic organizing pneumonia (COP); Desquamative interstitial pneumonia (DIP); Lymphocytic interstitial pneumonia (LIP); Nonspecific interstitial pneumonia (NSIP); Respiratory bronchiolitis-associated interstitial lung disease (RB-ILD)

Mesh:

Year:  2014        PMID: 24424167     DOI: 10.1016/j.autrev.2014.01.037

Source DB:  PubMed          Journal:  Autoimmun Rev        ISSN: 1568-9972            Impact factor:   9.754


  12 in total

Review 1.  Interstital lung disease in ANCA vasculitis.

Authors:  Marco A Alba; Luis Felipe Flores-Suárez; Ashley G Henderson; Hong Xiao; Peiqi Hu; Patrick H Nachman; Ronald J Falk; J Charles Jennette
Journal:  Autoimmun Rev       Date:  2017-05-04       Impact factor: 9.754

2.  Hydrogel-based delivery of Il-10 improves treatment of bleomycin-induced lung fibrosis in mice.

Authors:  Elya A Shamskhou; Michael J Kratochvil; Mark E Orcholski; Nadine Nagy; Gernot Kaber; Emily Steen; Swathi Balaji; Ke Yuan; Sundeep Keswani; Ben Danielson; Max Gao; Carlos Medina; Abinaya Nathan; Ananya Chakraborty; Paul L Bollyky; Vinicio A De Jesus Perez
Journal:  Biomaterials       Date:  2019-02-22       Impact factor: 12.479

3.  Evaluation of choroidal thickness, retinal vascular caliber, and nerve fiber layer thickness in idiopathic interstitial pneumonia.

Authors:  Erhan Ugurlu; Gokhan Pekel; Betul Cengiz; Kerem Bozkurt; Goksel Altinisik
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2017-04-28       Impact factor: 0.670

4.  Classification and Pathological Diagnosis of Idiopathic Interstitial Pneumonia.

Authors:  Zhihua Chen; Wenqiang Huang; Yibo Song
Journal:  Comput Intell Neurosci       Date:  2022-05-31

5.  Tannic acid alleviates experimental pulmonary fibrosis in mice by inhibiting inflammatory response and fibrotic process.

Authors:  Nandhine Rajasekar; Ayyanar Sivanantham; Amrita Kar; Santanu Kar Mahapatra; Rajesh Ahirwar; Rajesh K Thimmulappa; Sudhakar Gandhi Paramasivam; Rajasekaran Subbiah
Journal:  Inflammopharmacology       Date:  2020-05-05       Impact factor: 4.473

6.  Pan-transcriptome-based candidate therapeutic discovery for idiopathic pulmonary fibrosis.

Authors:  Yunguan Wang; Jaswanth K Yella; Sudhir Ghandikota; Tejaswini C Cherukuri; Harshavardhana H Ediga; Satish K Madala; Anil G Jegga
Journal:  Ther Adv Respir Dis       Date:  2020 Jan-Dec       Impact factor: 4.031

Review 7.  The ER Stress/UPR Axis in Chronic Obstructive Pulmonary Disease and Idiopathic Pulmonary Fibrosis.

Authors:  Mahmoud Aghaei; Sanaz Dastghaib; Sajjad Aftabi; Mohamad-Reza Aghanoori; Javad Alizadeh; Pooneh Mokarram; Parvaneh Mehrbod; Milad Ashrafizadeh; Ali Zarrabi; Kielan Darcy McAlinden; Mathew Suji Eapen; Sukhwinder Singh Sohal; Pawan Sharma; Amir A Zeki; Saeid Ghavami
Journal:  Life (Basel)       Date:  2020-12-22

Review 8.  State of the art in the diagnosis and management of interstitial lung disease.

Authors:  Maria T A Buzan; Carmen Monica Pop
Journal:  Clujul Med       Date:  2015-04-15

9.  The Protective Effect of Naringin against Bleomycin-Induced Pulmonary Fibrosis in Wistar Rats.

Authors:  Nergiz H Turgut; Haki Kara; Sahende Elagoz; Koksal Deveci; Huseyin Gungor; Emre Arslanbas
Journal:  Pulm Med       Date:  2016-02-10

10.  Metabolic heterogeneity of idiopathic pulmonary fibrosis: a metabolomic study.

Authors:  Yidan D Zhao; Li Yin; Stephen Archer; Catherine Lu; George Zhao; Yan Yao; Licun Wu; Michael Hsin; Thomas K Waddell; Shaf Keshavjee; John Granton; Marc de Perrot
Journal:  BMJ Open Respir Res       Date:  2017-06-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.